Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$63.94
Price-0.68%
-$0.44
1Y
Price
Market Cap
$8.954b
Mid
Price/Earnings 3y Avg5y Avg
40x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+25.0%
EBITDA Margin-9.3%
Net Profit Margin+5.1%
Free Cash Flow Margin+25.0%
EBITDA Margin-9.3%
Net Profit Margin+5.1%
Free Cash Flow MarginRevenue
$829.448m
+23258.2%
1y CAGR+7719.5%
3y CAGR+5808.6%
5y CAGREarnings
-$1.631m
+99.7%
1y CAGR-36.3%
3y CAGR-33.5%
5y CAGREPS
-$0.01
+98.6%
1y CAGR-25.6%
3y CAGR-24.9%
5y CAGRBook Value
$503.416m
$1.450b
Assets$947.022m
Liabilities$733.681m
DebtDebt to Assets
50.6%
4.4x
Debt to EBITDAFree Cash Flow
$156.886m
+126.0%
1y CAGR-10.6%
3y CAGR-64.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company